Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents including ranibizumab and aflibercept are used to treat patients with ocular disorders such as neovascular age-related macular degeneration (nAMD); however, the injections are associated with rare instances of severe ocular inflammation. This study compared severe ocular inflammation rates in patients treated with ranibizumab versus aflibercept. METHODS: United States physician-level claims data covering an 18-month period for each therapy were analyzed. The primary analysis compared severe ocular inflammation event rates per 1000 injections. Sensitivity and subgroup analyses evaluated the impact of factors including intraocular surgery, intravitreal antibiotic administration, and previous intravitreal injections. RESULTS: The analysis included 432,794 injection claims (ranibizumab n = 253,647, aflibercept n = 179,147); significantly, more unique severe ocular inflammation events occurred in patients receiving aflibercept than ranibizumab (1.06/1000 injections, 95% confidence interval [CI], 0.91-1.21, vs. 0.64/1000 injections, 95% CI 0.54-0.74; p < 0.0001). Comparable results were observed for analyses of patients who had undergone glaucoma or cataract surgeries, had antibiotic-associated endophthalmitis, had non-antibiotic-associated endophthalmitis, and were non-treatment-naive. In contrast, no significant differences in severe ocular inflammation claims were recorded in treatment-naive patients who had no record of anti-VEGF treatment in the 6 months preceding the index claim. No significant change occurred in the rate of severe ocular inflammation claims over time following ranibizumab treatment. CONCLUSIONS: Severe ocular inflammation was more frequent following intravitreal injection with aflibercept than with ranibizumab during routine clinical use in patients with nAMD. This highlights the importance of real-world, post-approval, observational monitoring of novel medicines, and may aid clinical decision-making, including choice of anti-VEGF agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Bloch, S. B., Larsen, M., & Munch, I. C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.10.016 · Cited by 377
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Time Trends in the Incidence and Causes of Blindness in Israel
Skaat, A., Chetrit, A., Belkin, M., Kinori, M., & Kalter-Leibovici, O. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.035 · Cited by 115
Dreyer, N. A., Velentgas, P., Westrich, K., & Dubois, R. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.3.301 · Cited by 107
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83
Murinello, S., Mullins, R. F., Lotery, A. J., Perry, V. H., & Teeling, J. L. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11821 · Cited by 51
Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303233 · Cited by 29
Self-citationVisual impairment certification secondary to ARMD in Leeds, 2005–2010: is the incidence falling?
Rostron, E., & McKibbin, M. (2012) · Eye · doi:10.1038/eye.2012.61 · Cited by 23
Cited by
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab
Monés, J., Srivastava, S. K., Jaffe, G. J., Tadayoni, R., Albini, T. A., Kaiser, P. K., Holz, F. G., Korobelnik, J.-F., Kim, I. K., Pruente, C., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.011 · Cited by 351
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
Baumal, C. R., Spaide, R. F., Vajzovic, L., Freund, K. B., Walter, S. D., John, V., Rich, R., Chaudhry, N., Lakhanpal, R. R., Oellers, P. R., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.017 · Cited by 312
Brolucizumab and immunogenicity
Sharma, A., Kumar, N., Parachuri, N., Sharma, R., Bandello, F., Kuppermann, B. D., & Loewenstein, A. (2020) · Eye · doi:10.1038/s41433-020-0853-9 · Cited by 51
Metadata
- Authors
- Souied, E. H., Dugel, P. U., Ferreira, A., Hashmonay, R., Lu, J., & Kelly, S. P.
- Venue
- Ophthalmic Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2016-02-08
- Volume
- 23
- Issue
- 2
- Pages
- 71-79
- ISSN
- 0928-6586 (ISSN-L)
- 1744-5086
- OpenAlex
- W2274444581
- Cited by
- 65
- References
- 9
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. https://app.cochat.ai/papers/10.3109/09286586.2015.1090004
- The paper
- Souied, E. H., Dugel, P. U., Ferreira, A., Hashmonay, R., Lu, J., & Kelly, S. P. (2016). Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Ophthalmic Epidemiology. https://doi.org/10.3109/09286586.2015.1090004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.